SEC Form 4 · accession 0000921895-19-000048

ENZON PHARMACEUTICALS, INC. · ENZN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

Jonathan Couchman

10% Owner · Other

Xstelos Corp.

10% Owner · Other

Couchman Family Fund

10% Owner · Other

Period of report

Apr 13, 2018

Accepted (ET)

Jan 9, 2019 · 8:53 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000727510

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.01 par value^F1,F2	Aug 15, 2018	P	20,600	$0.255	A	4,596,666	D
Common Stock, $0.01 par value^F1,F2,F5	Aug 16, 2018	P	8,800	$0.2588	A	4,605,466	D
Common Stock, $0.01 par value^F1,F2	Aug 20, 2018	P	67,200	$0.26	A	4,672,666	D
Common Stock, $0.01 par value^F1,F2,F3	Nov 12, 2018	P	100,000	$0.21	A	814,500	I	By Xstelos Corp.
Common Stock, $0.01 par value^F1,F2,F3	Nov 15, 2018	P	100,000	$0.21	A	914,500	I	By Xstelos Corp.
Common Stock, $0.01 par value^F1,F2,F3	Nov 16, 2018	P	2,500	$0.21	A	917,000	I	By Xstelos Corp.
Common Stock, $0.01 par value^F1,F2,F6,F3	Nov 19, 2018	P	15,000	$0.2196	A	932,000	I	By Xstelos Corp.
Common Stock, $0.01 par value^F1,F2,F3	Nov 21, 2018	P	40,050	$0.22	A	972,050	I	By Xstelos Corp.
Common Stock, $0.01 par value^F1,F2,F3	Dec 3, 2018	P	42,450	$0.22	A	1,014,500	I	By Xstelos Corp.
Common Stock, $0.01 par value^F1,F2,F3	Dec 4, 2018	P	450	$0.22	A	1,014,950	I	By Xstelos Corp.
Common Stock, $0.01 par value^F1,F2,F3	Dec 6, 2018	P	1,100	$0.22	A	1,016,050	I	By Xstelos Corp.
Common Stock, $0.01 par value^F1,F2,F3	Dec 7, 2018	P	2,500	$0.22	A	1,018,550	I	By Xstelos Corp.
Common Stock, $0.01 par value^F1,F2,F3	Dec 19, 2018	P	15,261	$0.23	A	1,033,811	I	By Xstelos Corp.
Common Stock, $0.01 par value^F1,F2,F7,F3	Dec 20, 2018	P	213,189	$0.2365	A	1,247,000	I	By Xstelos Corp.
Common Stock, $0.01 par value^F1,F2,F8,F3	Dec 21, 2018	P	312,523	$0.2691	A	1,559,523	I	By Xstelos Corp.
Common Stock, $0.01 par value^F1,F2	Jan 3, 2019	P	4,500	$0.255	A	4,677,166	D
Common Stock, $0.01 par value^F1,F2	Jan 4, 2019	P	2,500	$0.255	A	4,679,666	D
Common Stock, $0.01 par value^F1,F2	Jan 7, 2019	P	2,000	$0.255	A	4,681,666	D
Common Stock, $0.01 par value^F1,F2,F4	holding	—	—		—	400,000	I	By Couchman Family Fund

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation") and Xstelos Corp. ("Xstelos" and, together with Mr. Couchman and the Foundation, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose.
F2Due to the Securities and Exchange Commission's electronic filing system limitation of thirty line items on Table I, this Form 4 filing is part two of two.
F3Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
F4Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares.
F5The price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.2577 to $0.2600. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote 5.
F6The price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.2175 to $0.2200. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote 6.
F7The price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.2250 to $0.2500. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote 7.
F8The price reported is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $0.2500 to $0.2700. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote 8.